Fig. 4From: Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysisThe effect of SGLT2 inhibitors versus placebo on the risk of adverse events for the patients with HFmrEF/HFpEF. Forest plot for the SGLT2 inhibitors vs placebo in patients with HFmrEF/HFpEF: A Any serious adverse event; B Discontinuation of treatmentBack to article page